126 related articles for article (PubMed ID: 16809729)
1. Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded central venous access devices.
Moll S; Kenyon P; Bertoli L; De Maio J; Homesley H; Deitcher SR
J Clin Oncol; 2006 Jul; 24(19):3056-60. PubMed ID: 16809729
[TBL] [Abstract][Full Text] [Related]
2. Alteplase for the treatment of central venous catheter occlusion in children: results of a prospective, open-label, single-arm study (The Cathflo Activase Pediatric Study).
Blaney M; Shen V; Kerner JA; Jacobs BR; Gray S; Armfield J; Semba CP;
J Vasc Interv Radiol; 2006 Nov; 17(11 Pt 1):1745-51. PubMed ID: 17142704
[TBL] [Abstract][Full Text] [Related]
3. Alfimeprase.
Drugs R D; 2008; 9(3):185-90. PubMed ID: 18457471
[TBL] [Abstract][Full Text] [Related]
4. Drug evaluation: alfimeprase, a plasminogen-independent thrombolytic.
Shah AR; Scher L
IDrugs; 2007 May; 10(5):329-35. PubMed ID: 17487785
[TBL] [Abstract][Full Text] [Related]
5. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial--the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial.
Ponec D; Irwin D; Haire WD; Hill PA; Li X; McCluskey ER;
J Vasc Interv Radiol; 2001 Aug; 12(8):951-5. PubMed ID: 11487675
[TBL] [Abstract][Full Text] [Related]
6. Recombinant urokinase for restoration of patency in occluded central venous access devices. A double-blind, placebo-controlled trial.
Haire WD; Deitcher SR; Mullane KM; Jaff MR; Firszt CM; Schulz GA; Schuerr DM; Schwartz LB; Mouginis TL; Barton RP
Thromb Haemost; 2004 Sep; 92(3):575-82. PubMed ID: 15351854
[TBL] [Abstract][Full Text] [Related]
7. Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: a double-blinded, randomized trial.
Haire WD; Atkinson JB; Stephens LC; Kotulak GD
Thromb Haemost; 1994 Oct; 72(4):543-7. PubMed ID: 7878629
[TBL] [Abstract][Full Text] [Related]
8. Fibrolase: trials and tribulations.
Markland FS; Swenson S
Toxins (Basel); 2010 Apr; 2(4):793-808. PubMed ID: 22069611
[TBL] [Abstract][Full Text] [Related]
9. Treatment of occluded central venous catheters with alteplase: results in 1,064 patients.
Semba CP; Deitcher SR; Li X; Resnansky L; Tu T; McCluskey ER;
J Vasc Interv Radiol; 2002 Dec; 13(12):1199-205. PubMed ID: 12471182
[TBL] [Abstract][Full Text] [Related]
10. Recombinant tissue plasminogen activator for central venous access device occlusion.
Hooke C
J Pediatr Oncol Nurs; 2000 Jul; 17(3):174-8. PubMed ID: 10944865
[TBL] [Abstract][Full Text] [Related]
11. Alfimeprase to succeed Genentech's alteplase?
Vastag B
Nat Biotechnol; 2006 Aug; 24(8):875-6. PubMed ID: 16900112
[No Abstract] [Full Text] [Related]
12. The use of alteplase to restore patency of central venous lines in pediatric patients: a cohort study.
Choi M; Massicotte MP; Marzinotto V; Chan AK; Holmes JL; Andrew M
J Pediatr; 2001 Jul; 139(1):152-6. PubMed ID: 11445811
[TBL] [Abstract][Full Text] [Related]
13. Safe and cost effective use of alteplase for the clearance of occluded central venous access devices.
Timoney JP; Malkin MG; Leone DM; Groeger JS; Heaney ML; Keefe DL; Klang M; Lucarelli CD; Muller RJ; Eng SL; Connor M; Small TN; Brown AE; Saltz LB
J Clin Oncol; 2002 Apr; 20(7):1918-22. PubMed ID: 11919252
[TBL] [Abstract][Full Text] [Related]
14. Alfimeprase: a novel recombinant direct-acting fibrinolytic.
Deitcher SR; Funk WD; Buchanan J; Liu S; Levy MD; Toombs CF
Expert Opin Biol Ther; 2006 Dec; 6(12):1361-9. PubMed ID: 17223743
[TBL] [Abstract][Full Text] [Related]
15. Alteplase for the management of occluded central venous access devices: safety considerations.
Smith LH
Clin J Oncol Nurs; 2008 Feb; 12(1):155-7. PubMed ID: 18258586
[No Abstract] [Full Text] [Related]
16. Safety, dose, and timing of reteplase in treating occluded central venous catheters in children with cancer.
Terrill KR; Lemons RS; Goldsby RE
J Pediatr Hematol Oncol; 2003 Nov; 25(11):864-7. PubMed ID: 14608195
[TBL] [Abstract][Full Text] [Related]
17. Recombinant tissue plasminogen activator in the treatment of central venous catheter occlusion in children.
Jacobs BR; Haygood M; Hingl J
J Pediatr; 2001 Oct; 139(4):593-6. PubMed ID: 11598611
[TBL] [Abstract][Full Text] [Related]
18. Hemorrhagic profile of the fibrinolytic alfimeprase after ischemia and reperfusion.
Lu A; Kurosawa Y; Luskey K; Pyne-Geithman G; Caudell D; Clark J
Neurol Res; 2009 Mar; 31(2):209-14. PubMed ID: 19298764
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of alfimeprase for peripheral arterial thrombolysis.
Ouriel K; Cynamon J; Weaver FA; Dardik H; Akers D; Blebea J; Gruneiro L; Toombs CF; Wang-Clow F; Mohler M; Pena L; Wan CY; Deitcher SR
J Vasc Interv Radiol; 2005 Aug; 16(8):1075-83. PubMed ID: 16105919
[TBL] [Abstract][Full Text] [Related]
20. Does low-dose heparin maintain central venous access device patency?: a comparison of heparin versus saline during a period of heparin shortage.
Jonker MA; Osterby KR; Vermeulen LC; Kleppin SM; Kudsk KA
JPEN J Parenter Enteral Nutr; 2010; 34(4):444-9. PubMed ID: 20631392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
